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Hematopoietic stem cells (HSCs) and multipotent
hematopoietic progenitors (MPPs) are routinely iso-
lated using various markers but remain heteroge-
neous. Here we show that four SLAM family markers,
CD150, CD48, CD229, and CD244, can distinguish
HSCs and MPPs from restricted progenitors and
subdivide them into a hierarchy of functionally
distinct subpopulations with stepwise changes
in cell-cycle status, self-renewal, and reconstitu-
ting potential. CD229 expression largely distin-
guished lymphoid-biased HSCs from rarely dividing
myeloid-biased HSCs, enabling prospective enrich-
ment of these HSC subsets. Differences in CD229
and CD244 expression resolved CD150CD48/low
Lineage/lowSca-1+c-Kit+ cells into a hierarchy of
highly purified MPPs that retained erythroid and
platelet potential but exhibited progressive changes
in mitotic activity and reconstituting potential. Use
of these markers, and reconstitution assays, showed
that conditional deletion of Scf from endothelial cells
and perivascular stromal cells eliminated the vast
majority of bone marrow HSCs, including nearly all
CD229/low HSCs, demonstrating that quiescent
HSCs are maintained by a perivascular niche.
INTRODUCTION
A number of markers permit the prospective identification and
isolation of hematopoietic stemcells (HSCs) andmultipotent pro-
genitors (MPPs) (Bryder et al., 2006). In the adult mouse, all multi-
potent cells are contained in the Lineage/lowSca-1+c-Kit+ (LSK)
fraction of bone marrow cells, though this population is very het-
erogeneous (Spangrude et al., 1988; Ikuta and Weissman, 1992;
Uchida et al., 1994). Higher levels of HSC purity can be achieved
by selecting the Thy-1low subset of Lineage/lowSca-1+ cells
(Spangrude et al., 1988) and by distinguishing cells with different
levels of Mac-1 and CD4 expression: HSCs are Thy1lowSca-1+
LineageMac-1CD4c-Kit+, while MPPs are Thy1lowSca-1+
LineageMac-1lowCD4low (Morrison andWeissman, 1994;Morri-
son et al., 1997). Higher levels of HSC purity are also achieved by102 Cell Stem Cell 13, 102–116, July 3, 2013 ª2013 Elsevier Inc.selecting the subset of LSK cells that is CD34 negative/low
(Osawa et al., 1996), Flt3 negative (Christensen and Weissman,
2001; Adolfsson et al., 2005; Yang et al., 2005), or effluxes
Hoechst 33342 (Goodell et al., 1996).
HSCs can also be isolated using the SLAM family markers
CD150 (also known as Slamf1) and CD48 (Slamf2) as
CD150+CD48 cells (Forsberg et al., 2005; Kiel et al., 2005,
2008; Kim et al., 2006; Yilmaz et al., 2006). Addition of LSK
markers to these SLAM family markers only modestly increases
HSC purity but is useful to confirm the purity of the cells during
sorting (Kiel et al., 2005, 2008; Kim et al., 2006; Yilmaz et al.,
2006). MPPs can be isolated by selecting CD150CD48LSK
cells (Kiel et al., 2008). Consistent with this, the self-renewal
and reconstituting potentials of HSCs decline as CD150 expres-
sion levels decline (Papathanasiou et al., 2009; Beerman et al.,
2010; Morita et al., 2010).
Despite markers that can give high levels of HSC and MPP
purity, HSC and MPP populations remain functionally heteroge-
neous. Most CD150+CD48LSK HSCs are in G0 and only 3%
are in S/G2/M phase of the cell cycle, indicating that this popula-
tion contains very few cycling cells (Kiel et al., 2007). Nonethe-
less, the quiescent cells in this population are heterogeneous
with respect to the rate at which they enter cycle over time,
with about 80% going into cycle every 12 days and about 20%
of the cells entering cycle every 100 days (Wilson et al., 2008;
Foudi et al., 2009). HSCs are also heterogeneous with respect
to the ratio of myeloid to lymphoid cells that they generate
upon transplantation into irradiated mice (Mu¨ller-Sieburg et al.,
2002; Dykstra et al., 2007; Kent et al., 2009; Beerman et al.,
2010; Challen et al., 2010; Morita et al., 2010) and with respect
to their self-renewal potential upon transplantation (Ema et al.,
2005; Benveniste et al., 2010; Morita et al., 2010). However, lim-
itations in the ability to purify each subset of HSCs has meant
that some subsets of HSCs have often been characterized
based on retrospective analyses of reconstitution patterns in
irradiated mice (Copley et al., 2012).
MPPs are heterogeneous with respect to reconstitution
kinetics in irradiated mice and the types of blood cells they pro-
duce (Morrison and Weissman, 1994; Morrison et al., 1997;
Adolfsson et al., 2005; Yang et al., 2005; Forsberg et al., 2006).
However, many of the MPP populations that have been studied
are relatively impure: many cells must be transplanted to de-
tectably reconstitute irradiated mice. The dependence on such
heterogeneous populations has confounded the ability to char-
acterize these cells—new markers are required.
Cell Stem Cell
SLAM Markers Distinguish HSC/MPP HeterogeneityThe inability to resolve distinct subpopulations of HSCs has
impeded our ability to characterize their niche. HSCs reside in
a perivascular niche in which endothelial cells and perivascular
stromal cells promote HSC maintenance by producing SCF
and Cxcl12 (Sugiyama et al., 2006; Me´ndez-Ferrer et al., 2010;
Ding et al., 2012; Greenbaum et al., 2013; Ding and Morrison,
2013). Conditional deletion of Scf or Cxcl12 from osteoblasts
did not affect HSC frequency or function (Ding et al., 2012;
Greenbaum et al., 2013; Ding and Morrison, 2013). However,
conditional deletion of Scf or Cxcl12 from endothelial cells or
from Leptin Receptor-expressing perivascular stromal cells did
deplete bone marrow HSCs. Conditional deletion of Scf from
both endothelial cells and perivascular stromal cells in Tie2-
Cre; Lepr-Cre; Scffl/mice eliminated most HSCs based on sur-
face marker phenotype (Ding et al., 2012). However, others have
speculated that only ‘‘activated’’ HSCs reside in a perivascular
niche. Without markers to distinguish ‘‘activated’’ HSCs, this
idea has been impossible to directly test.
In this study, we extended our analysis of the SLAM family and
found that four SLAM family markers, CD150 (Slamf1), CD48
(Slamf2), CD229 (Slamf3), and CD244 (Slamf4), subdivided adult
mouse bone marrow LSK cells into seven functionally distinct
fractions of cells: two that contained HSCs, three that contained
MPPs, and two that contained restricted hematopoietic progen-
itor cells (HPCs). These fractions formed a hierarchy that ex-
hibited progressive changes in cell-cycle kinetics, self-renewal
capacity, and reconstituting potential. These markers thus
allowed us to distinguish different subsets of HSCs and MPPs
while prospectively isolating each population to a high degree
of purity. Use of thesemarkers, along with reconstitution assays,
showed that the vast majority of phenotypically and functionally
identifiable HSCs were lost when Scf was conditionally deleted
from endothelial cells and perivascular stromal cells in the
bone marrow of adult Tie2-Cre; Lepr-Cre; Scffl/ mice. Quies-
cent HSCs therefore depend upon a perivascular niche for their
maintenance.
RESULTS
CD150, CD48, CD229, and CD244 Subdivide LSK Cells
into Distinct Fractions
Lineage/lowSca-1+c-kit+ (LSK) cells can be subdivided
into four fractions based on the expression of CD150 and
CD48 (Figure 1A): HSCs are CD150+CD48LSK, MPPs
are CD150CD48LSK, and CD150CD48+LSK (HPC-1) and
CD150+CD48+LSK (HPC-2) cells contain heterogeneous
restrictedprogenitors (Kiel et al., 2005,2008). In thepresent study,
we investigated the expression of CD229 (Slamf3), CD244
(Slamf4), CD84 (Slamf5), and Ly108 (Slamf6). CD84 and Ly108
were similarly expressed by almost all LSK cells (Figures 1B
and 1C). In contrast, CD229 was heterogeneously expressed by
HSCs and HPC-2 cells (Figure 1D) and CD244 was heteroge-
neously expressed by HSCs, MPPs, and HPC-2 cells (Figure 1E).
Figure S1 available online shows the expression of CD229,
CD244, CD84, and Ly108 on other subpopulations of hematopoi-
etic progenitors.
Differences in CD229 and CD244 expression subdivided
CD150+CD48/lowLSK HSCs into two fractions and CD150
CD48/lowLSK MPPs into three fractions. CD150CD48+LSKHPC-1 cells were almost entirely CD229+CD244+ (Figure 1F).
CD150+CD48+LSK HPC-2 cells were heterogeneous for
CD229 and CD244, but we did not separately analyze the
two fractions because they were too rare (Figure 1F). We also
did not characterize CD229+CD244+ HSCs because they nearly
disappeared when we used stringent HSC gates (data not
shown). To assess whether SLAM family markers distin-
guished functionally different subpopulations of HSCs and
MPPs, we focused on CD150+CD48/lowCD229/low CD244
LSK HSC-1 cells, CD150+CD48/lowCD229+CD244LSK
HSC-2 cells, CD150CD48/lowCD229/lowCD244LSK MPP-1
cells, CD150CD48/lowCD229+CD244LSK MPP-2 cells,
CD150CD48/lowCD229+CD244+LSK MPP-3 cells, CD150
CD48+LSK HPC-1 cells, and CD150+CD48+LSK HPC-2 cells
(Figure 1G).
We first analyzed the expression of markers used previously
to distinguish HSCs and MPPs including CD34, Flt3 (also
known as Flk2), Thy1, EPCR, and ESAM (Spangrude et al.,
1988; Osawa et al., 1996; Christensen and Weissman, 2001;
Adolfsson et al., 2005; Yang et al., 2005; Balazs et al., 2006;
Ooi et al., 2009; Yokota et al., 2009). The HSC-1 population
contained more CD34/lowFlt3 cells than HSC-2 cells, sug-
gesting that HSC-1 cells were more primitive (Figure S2A).
The MPP-1, MPP-2, and MPP-3 fractions contained primarily
CD34/lowFlt3 cells, CD34+Flt3/+ cells, and CD34+Flt3+ cells,
respectively, suggesting that MPP-1 cells were most primi-
tive and MPP-3 cells were least primitive (Figure S2A). Almost
all cells in the HSC-1, HSC-2, MPP-1, MPP-2, and MPP-3
fractions expressed Thy1, EPCR, and ESAM, though the
expression levels were higher in HSCs than in MPPs (Figures
S2B–S2D).
Different Cell-Cycle Distributions among SLAM-Defined
HSC and MPP Populations
We used Ki-67 and propidium iodide (PI) staining to estimate the
frequencies of G0 (Ki-67
; 2N DNA content), G1 (Ki-67
+; 2N DNA
content), and S/G2/M (Ki-67
+; >2N DNA content) cells in each
population (Figure S3A). According to these markers, more
than 90% of HSC-1, HSC-2, MPP-1, and MPP-2 cells were in
G0 at any one time, but significantly fewer MPP-3 cells were in
G0 (88% ± 3%), and the HPC-1 and HPC-2 fractions were
actively cycling (Figures 2A–2C). The frequencies of cells in G1
and S/G2/M generally increased as cells transitioned through
the HSC-2,MPP-1,MPP-2,MPP-3, HPC-1, andHPC-2 fractions
(Figures 2A–2C). The only exception was that HSC-2 cells
included a slightly higher frequency of cells in S/G2/M (2.5% ±
1.1%) as compared to MPP-1 and MPP-2 cells (both <1%)
(Figures 2A–2C).
We next administered 5-bromo-deoxyuridine (BrdU) for 24 hr
or for 7 days to mice, then analyzed each subpopulation of
HSCs and MPPs. The rate of BrdU incorporation increased
progressively from the HSC-1 fraction through the HPC-2
population (Figures 2D and 2E). HSC-1 cells were most highly
quiescent, with only 3.7% ± 1.5% (mean ± SD) and 23% ± 5%
BrdU+ cells after 24 hr and 7 days, respectively (Figures 2D
and 2E). The rates of BrdU incorporation into HSC-2, MPP-1,
and MPP-2 cells were significantly higher. Almost all MPP-3,
HPC-1, and HPC-2 cells incorporated BrdU over a 7 day period
(Figures 2D and 2E).Cell Stem Cell 13, 102–116, July 3, 2013 ª2013 Elsevier Inc. 103
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Figure 2. Cell-Cycle Status of Each
Hematopoietic Stem and Progenitor Cell
Fraction
(A–C) The frequency of cells in G0 (A; Ki-67
, 2N
DNA content), G1 (B; Ki-67
+, 2N DNA content), and
S/G2/M (C; Ki-67
+, >2N DNA content) phases of
the cell cycle.
(D and E) The frequency of BrdU+ cells in each
fraction after 24 hr (D) or 7 days (E) of BrdU
administration.
(F–H) Expression of histone H2B-GFP was
induced in hematopoietic cells by doxycycline
administration for 6 weeks then chased for
6 weeks (F), 12 weeks (G), or 24 weeks (H) without
doxycycline to monitor the rate of H2B-GFP dilu-
tion. Filled and open bars represent the proportion
of GFPhi and GFPlow cells, respectively, in each
population. The gating scheme used to identify
GFPhi and GFPlow cells is shown in Figures S3B
and S3C. Data represent mean ± SD from two in-
dependent experiments with a total of four mice (F
and G) or three independent experiments with a
total of three to seven mice (A–E and H). *p < 0.05;
**p < 0.01; ***p < 0.001 by Student’s t test. Sta-
tistical analyses in (F)–(H) compared only the fre-
quency of GFPhi cells among cell populations. See
also Figure S3.
Cell Stem Cell
SLAM Markers Distinguish HSC/MPP HeterogeneityWe also used histone H2B-GFP label retention to monitor the
division history of HSC and MPP subpopulations (Wilson et al.,
2008; Foudi et al., 2009). The Col1A1-H2B-GFP; Rosa26-M2-
rtTA double transgenic mice (Foudi et al., 2009) were adminis-
tered doxycycline or 6 weeks to label all hematopoietic cells
with H2B-GFP then chased for 6, 12, or 24 weeks without doxy-
cycline to monitor the rate at which H2B-GFP was lost over time.
Figures S3B–S3D show the gates used to distinguish GFPhigh
from GFPlow cells. After 6 weeks of chase, most HSC-1, HSC-2,
MPP-1, and MPP-2 cells retained high levels of GFP but the
frequency of GFPhigh cells decreased progressively among these
populations (Figure 2F). In contrast, few MPP-3 cells retained
high levels of GFP and the HPC-1 and HPC-2 populations lost
almost all GFPhigh cells (Figure 2F). After 12 weeks of chase,
HSC-1 cells included significantly more GFPhigh cells than
HSC-2 cells, andMPP-1 cells included significantlymoreGFPhigh
cells than MPP-2 cells (Figure 2G). Our data are thus consistent
with previously published results (Morrison and Weissman,
1994; Foudi et al., 2009) in indicating that many MPPs divide at
similar rates as HSCs. Similar trends were observed after
24weeks of chase, thoughby this time fewcells in any population
retained high levels of GFP (Figure 2H).Figure 1. Expression of the SLAM Family Markers CD84, Ly108, CD229
(A) Gating strategy for LSK cells (left and middle left) and expression of C
CD150CD48/lowLSK, CD150CD48+LSK, and CD150+CD48+LSK fractions we
blood cells, and dead cells were excluded prior to analysis.
(B–E) Cell surface staining for CD84/Slamf5 (B), Ly108/Slamf6 (C), CD229/Slamf3
the indicated antigens and shaded areas indicate background fluorescence in c
(F) Flow cytometry plots showing combined CD229 and CD244 staining in each
(G) Summary of LSK stem and progenitor cell fractions subdivided according to
(A and D–G) independent experiments. See also Figures S1 and S2.HSC-1 and HSC-2 Contain a Hierarchy of Long-Term
Multilineage Reconstituting Cells
Five HSC-1 or HSC-2 cells isolated from UBC-GFP mice were
transplanted into irradiated recipient mice along with 200,000
recipient bone marrow cells. UBC-GFP donors were used to
assess donor contributions to erythrocyte and platelet reconsti-
tution, in addition to myeloid, B, and T cells (Figures S4A and
S4B). Both fractions gave long-term multilineage reconstitution
in most recipients (Figures 3A and 3B). Ninety-three percent of
recipients that received HSC-1 cells had long-term myeloid
and lymphoid reconstitution by donor cells (Figure 3C). Fifty-
four percent of recipients that received HSC-2 cells had long-
term myeloid and lymphoid reconstitution (Figure 3C). Another
34% of recipients of HSC-2 cells exhibited transient reconstitu-
tion by myeloid and lymphoid cells, suggesting that HSC-2
cells represent a transitional population between long-term
self-renewing HSCs and transiently self-renewing MPPs.
All recipients of five HSC-1 cells had donor-derived HSC-1,
HSC-2, MPP-1, MPP-2, MPP-3, HPC-1, HPC-2, CMP, GMP,
MEP, and CLP cells in their bone marrow (Figure 3D; see
Figure S4C for individual mice). Consistent with our cell-cycle
analysis (Figure 2), this suggests that HSC-1 includes the most, and CD244 by LSK Hematopoietic Stem and Progenitor Cells
D150 and CD48 by LSK cells (middle right). The CD150+CD48/lowLSK,
re labeled as HSC, MPP, HPC-1, and HPC-2, respectively (right). Doublets, red
(D), and CD244/Slamf4 (E). Solid lines indicate staining with antibodies against
ontrols stained with all antibodies except for the indicated antigen.
cell fraction.
CD229 and CD244 staining. Data represent mean ± SD from 3 (B and C) or 11
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Figure 3. The HSC-1 and HSC-2 Populations Form a Hierarchy of Long-Term Multilineage Reconstituting Cells
(A and B) Long-term competitive reconstitution assay in which five GFP+ donor cells from the HSC-1 (A) or HSC-2 (B) population were transplanted into irradiated
recipient mice along with 200,000 recipient bone marrow cells. Each line represents the frequency of donor-derived cells in the blood of a single recipient.
(C) Summary of the results from the primary transplants in (A) and (B). Recipients were considered long-term reconstituted if donor myeloid cells were more than
1% of blood cells for at least 16 weeks after transplantation. M, Mac-1+ myeloid cells; B, B220+ B cells; T, CD3+ T cells.
(D and E) The frequencies of donor-derived hematopoietic stem and progenitor cells in the bone marrow of mice that were long-term reconstituted by five HSC-1
(D) or five HSC-2 (E) cells at 17 to 25 weeks after primary transplantation.
(legend continued on next page)
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SLAM Markers Distinguish HSC/MPP Heterogeneityprimitive HSCs. Recipients of five HSC-2 cells had donor-
derived HSC-2 cells in their bone marrow in addition to MPP-1,
MPP-2,MPP-3, HPC-1, HPC-2, CMP, GMP,MEP, and CLP cells
(five of five mice tested; Figures 3E and S4D); however, recipi-
ents of HSC-2 cells usually did not have donor-derived HSC-1
cells (Figure S4D). This suggests that HSC-1 cells give rise to
HSC-2 cells but that HSC-2 cells have little capacity to form
HSC-1 cells.
We also transplanted single HSC-1 or HSC-2 cells along with
200,000 bone marrow cells into irradiated mice. Fourteen of 30
mice that received one HSC-1 cell were reconstituted by donor
cells 16 weeks after transplantation, and 12 of these mice
exhibited long-term multilineage reconstitution, suggesting that
at least 40% of HSC-1 cells are HSCs. The reconstituted recip-
ients of HSC-1 cells exhibited high levels of donor cells at
16 weeks after transplantation (27% ± 24% of nucleated blood
cells, mean ± SD), usually myeloid-biased reconstitution (Fig-
ure 3F). Nine of 30 mice that received one HSC-2 cell were re-
constituted by donor cells 16weeks after transplantation, usually
lymphoid-biased reconstitution (Figure 3G). Only four of these
recipients were long-termmultilineage reconstituted, suggesting
that at least 13% of HSC-2 cells were HSCs. The reconstituted
recipients of HSC-2 cells had lower levels of donor cells
(13% ± 15% of blood cells, mean ± SD) than recipients of
HSC-1 cells (Figure 3G).
Based on the criteria used to distinguish myeloid-biased,
balanced, and lymphoid-balanced clones (Mu¨ller-Sieburg
et al., 2002), 79% of HSC-1 cells were myeloid biased, 7%
were balanced, and 14% were lymphoid biased (Figure S4E).
Among HSC-2 cells, 22% were myeloid biased, 22% were
balanced, and 56% were lymphoid biased (Figure S4E). Based
on the criteria used by Dykstra et al. (2007), the HSC-1 popula-
tion contained 57% a cells, 21% b cells, 7% g cells, and 14%
d cells (Figure S4F). The HSC-2 population contained 11%
a cells, 11% b cells, 22% g cells, and 56% d cells (Figure S4F).
SLAM family markers thus make it possible to prospectively
enrich subpopulations of HSCs that were retrospectively
analyzed in prior studies based on reconstitution patterns in
irradiated mice.
We also transplanted five CD45.1+ HSC-1 cells and five
CD45.2+ HSC-2 cells into irradiated CD45.1+CD45.2+ (heterozy-
gous) recipient mice along with 200,000 CD45.1+CD45.2+ recip-
ient whole bone marrow cells. As expected, HSC-1 cells gave
significantly higher levels of overall reconstitution, particularly
in the myeloid lineage (Figure 3H).
To assess self-renewal potential, we transplanted five million
bone marrow cells from primary recipients that were long-term
multilineage reconstituted by donor cells into irradiated second-
ary recipients. Bone marrow from nine recipients of five HSC-1
cells was transplanted into a total of 32 secondary recipients.
Twenty-six of these 32 secondary recipients of HSC-1 cells(F and G) Clonal analysis of HSC-1 and HSC-2 cells. Single GFP+ HSC-1 (F) or HS
along with 200,000 recipient bone marrow cells. Some of these mice were lo
reconstituted.
(H) Long-term competitive reconstitution assay in which five CD45.1+ HSC
CD45.1+CD45.2+ recipient mice along with 200,000 CD45.1+CD45.2+ bone mar
recipient mice per treatment. Data in other panels are from two (A, B, D, and E) o
t test. See also Figure S4.were long-term multilineage reconstituted by donor cells (Fig-
ures 4A and 4C). At 17 to 25 weeks after secondary transplanta-
tion, most secondary recipients had donor HSC-1, HSC-2,
MPP-1, MPP-2, and MPP-3 cells as well as all of the restricted
progenitor populations that we examined (Figure 4D). HSC-1
cells thus have long-term self-renewal potential and form all
of the other stem and progenitor cell populations that we
examined.
Five long-term multilineage reconstituted recipients of five
HSC-2 cells were transplanted into a total of 17 surviving sec-
ondary recipients. Eight of these 17 secondary recipients were
long-termmultilineage reconstituted by donor cells and the other
nine secondary recipients were transiently multilineage reconsti-
tuted (Figures 4B and 4C). The secondary recipients of HSC-2
cells that exhibited long-term multilineage reconstitution
exhibited declining levels of donor myeloid cells, in contrast to
secondary recipients of HSC-1 cells that usually exhibited
increasing levels of donor myeloid cells over time (compare Fig-
ures 4A and 4B). At 17 to 25 weeks after secondary transplanta-
tion, most secondary recipients of HSC-2 cells lacked donor
HSC-1, HSC-2, or MPPs (Figure 4E). Secondary recipients of
HSC-2 cells exhibited significantly lower levels of donor cell
reconstitution than secondary recipients of HSC-1 cells (Fig-
ure 4F). HSC-2 cells therefore appear to have more limited
self-renewal capacity than HSC-1 cells.
The HSC-2 population can be further subdivided by CD34
expression (Figure S2A). Nine out of 12 recipients of five
CD34/low HSC-2 cells were long-term multilineage reconsti-
tuted. In contrast, none of the recipients of five CD34+ HSC-2
cells were long-term multilineage reconstituted, though they
showed transient multilineage or lymphoid-only reconstitution
(Figure S4G). These data indicate that CD34+ HSC-2 cells have
less HSC activity than CD34/low HSC-2 cells, as expected
(Osawa et al., 1996).
We compared the gene expression profiles of HSC-1 and
HSC-2 cells with gene sets for megakaryocyte/erythrocyte
(MkE) lineage cells, granulocyte/macrophage (GM) lineage cells,
lymphoid lineage cells (Ma˚nsson et al., 2007), and fetal liver
HSCs (He et al., 2011). The MkE gene set was significantly
enriched in HSC-1 cells, whereas GM and lymphoid gene sets
were significantly enriched in HSC-2 cells (Figure S4H). Fetal
liver HSC-associated genes were significantly enriched in
HSC-1 cells (Figure S4H). These results are consistent with our
data, suggesting that HSC-1 cells are more primitive than
HSC-2 cells.
MPP-1 Cells Include Intermediate and Transiently
Reconstituting Progenitors
Upon competitive transplantation of five MPP-1 cells into irradi-
ated mice, only one of ten recipients was long-term multilineage
reconstituted by donor cells (Figures 5A and 5B). Six of tenC-2 (G) cells were transplanted into 30 irradiated recipient mice per population
ng-term multilineage reconstituted and some were transiently multilineage
-1 cells and five CD45.2+ HSC-2 cells were transplanted into irradiated
row cells. Data represent mean ± SD from one experiment with a total of 13
r three (C and G) independent experiments. *p < 0.05; **p < 0.01 by Student’s
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Figure 4. Serial Transplantation Reveals that HSC-1 Cells Have More Self-Renewal Potential than HSC-2 Cells
(A and B) Five million bone marrow cells from primary recipients that were long-term reconstituted by five HSC-1 (A) or five HSC-2 (B) cells were transplanted into
secondary recipient mice. The secondary recipient mice were assigned numbers that corresponded to the numbers of the primary recipient mice shown in
Figures 3A and 3B. For example, the mean ± SD for the frequency of donor blood cells in secondary recipients of cells from primary recipient 1 in Figure 3A is
shown as line 1 in (A). Data are from two independent experiments with three to four secondary recipients per primary donor.
(legend continued on next page)
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SLAM Markers Distinguish HSC/MPP Heterogeneityrecipients were transiently multilineage reconstituted and the re-
maining recipients were transiently reconstituted only in the
myeloid lineage. At a dose of 25 MPP-1 cells, five of five recipi-
ents were long-term multilineage reconstituted (Figures 5C and
5D). However, the levels of myeloid reconstitution in these
mice tended to decline over time (Figure 5C), and when we
analyzed the bone marrow of these mice 17 weeks after trans-
plantation, none of the recipients had donor-derived HSC-1 cells
(Figure 5E). Multiple recipients had donor-derived MPP-1, MPP-
2, MPP-3, HPC-1, HPC-2, as well as various restricted progeni-
tor cells.
To assess self-renewal potential, we performed secondary
transplants of bone marrow cells from the primary recipients of
25 MPP-1 cells at 17 weeks after transplantation. Two primary
recipients gave long-term multilineage reconstitution in the sec-
ondary recipients (1 and 5), two gave only transient multilineage
reconstitution, and one gave only T lineage reconstitution (Fig-
ure 5F). A minority of MPP-1 cells retains the ability to give
long-term multilineage reconstitution, but these cells appear to
have intermediate self-renewal potential and little ability to
form HSC-1 or HSC-2 cells. The HSC-2 and MPP-1 populations
have successively reduced reconstituting and self-renewal
potentials relative to HSC-1 cells.
MPP-2 and MPP-3 Are Transiently Reconstituting
Multipotent Progenitors
Competitive transplantation of 5 or 25 CD150CD48/low
CD229+CD244LSK MPP-2 cells into irradiated mice yielded
transient multilineage reconstitution in nearly all recipients (Fig-
ures 6A and 6C). About half of the recipients of five MPP-2 cells
and all six of the recipients of 25 MPP-2 cells were transiently
reconstituted by donor erythrocytes and platelets (Figures 6A
and 6C). None of the recipients were long-term reconstituted.
SLAM family markers can therefore be used to isolate a highly
purified population of MPPs, from which only five cells can
give transient multilineage reconstitution in most recipients,
including within the erythroid and platelet lineages.
We also competitively transplanted 5 or 25 CD150CD48/low
CD229+CD244+LSKMPP-3 cells into irradiatedmice. Recipients
of 25 MPP-3 cells were all transiently multilineage reconstituted,
though at levels that were significantly (p < 0.01 at 4 weeks) lower
than in recipients of 25MPP-2 cells (Figures 6B and 6C). Myeloid
chimerism in recipients of 25 MPP-3 cells also appeared to be
lost earlier (4–6 weeks after transplantation) than in recipients
of 25 MPP-2 cells (6–8 weeks after transplantation). Four of
five recipients of 25 MPP-3 cells were also transiently reconsti-
tuted by platelets and erythrocytes (Figures 6B and 6C). Recipi-
ents of five MPP-3 cells exhibited transient reconstitution in the
myeloid and/or B lineages (Figures 6B and 6C). Two to three of
the recipients of five MPP-3 cells were reconstituted by donor
platelets and erythrocytes (Figures 6B and 6C). None of the
recipients were long-term reconstituted. MPP-3 cells therefore(C) Summary of secondary transplantation results from (A) and (B).
(D and E) The frequencies of donor-derived hematopoietic stem and progenit
transplantation. As in (A) and (B), the secondary recipient mice are numbered acc
SD from three to four secondary recipient mice per primary recipient.
(F) The frequencies of donor-derived hematopoietic stem and progenitor cells
secondary recipients total) and HSC-2 (mean ± SD from the data in E, n = 17 seinclude multipotent progenitors, though these cells reconstitute
more transiently and at lower levels than MPP-2 cells.
HPC-1 and HPC-2 Cells Contain a Mixture of Restricted
Progenitors
Most recipients of five HPC-1 cells were not detectably recon-
stituted by donor cells but two were transiently reconstituted
by donor B cells (Figure 6F). Four of five recipients of 25
HPC-1 cells were transiently reconstituted by B cells, with or
without T cells (Figures 6D and 6F). Only one of the recipients
of 25 HPC-1 cells was transiently reconstituted by platelets
and erythrocytes. Seven of eight recipients of 200 HPC-1 cells
were transiently reconstituted by donor myeloid and B cells,
four of which also had donor erythrocytes but only one of
which had platelets (Figure 6F). These data suggest that
HPC-1 cells are a heterogeneous population of restricted pro-
genitors that includes early lymphoid progenitors as well as
some cells that give very low levels of transient myeloerythroid
reconstitution. The kinetics of B lineage reconstitution by
HPC-1 cells is earlier than from MPP-3 cells (compare Figure 6D
to 6B), suggesting that HPC-1 lymphoid progenitors are more
mature than the multipotent MPP-3 cells. HPC-1 cells are
therefore the first population from which multilineage reconsti-
tution was not evident from small doses of cells and the only
LSK population that rarely formed platelets. Most HPC-1 cells
appeared to be restricted progenitors that lacked megakaryo-
cytic potential.
We competitively transplanted 5, 25, or 200 CD150+CD48+
LSK HPC-2 cells into irradiated recipient mice. Most recipients
of 5 or 25 HPC-2 cells were not detectably reconstituted by
donor cells, but most recipients of 200 HPC-2 cells were
transiently reconstituted by very low levels of donor erythro-
cytes and platelets and some were transiently reconstituted
by very low levels of donor myeloid and B cells (Figures 6E
and 6F). HPC-2 cells appear to contain a heterogeneous collec-
tion of restricted progenitors with limited reconstituting potential
in vivo.
To better understand the relationship between the SLAM-
defined MPPs that we studied and previously characterized
MPPs, we assessed SLAM family marker expression within
the CD34/lowFlt3+LSK, CD34+Flt3LSK, and CD34+Flt3+LSK
populations (Figure S5A). SLAM family markers resolved Flt3+
CD34+LSK cells into four distinct subsets of cells in the MPP-
2 (8% ± 3% of Flt3+LSK cells), MPP-3 (15% ± 3% of Flt3+LSK
cells), HPC-1 (75% ± 5% of Flt3+LSK cells), and HPC-2
(0.7% ± 0.2% of Flt3+LSK cells) populations (Figure S5A). Trans-
plantation of 25 cells from the Flt3+ fractions of these popula-
tions into irradiated mice indicated that the Flt3+ MPP-2,
MPP-3, and HPC-2 cells each gave rise to platelets and mega-
karyocytes in vivo, while the Flt3+ HPC-1 cells (that represented
most of the cells in the CD34+Flt3+LSK population) did not
(Figure S6).or cells in the bone marrow of secondary recipient mice 17–25 weeks after
ording to the primary recipient from which they received cells. Data are mean ±
in all secondary recipients of HSC-1 (mean ± SD from the data in D, n = 32
condary recipients total) cells.
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Figure 5. MPP-1 Cells Contain a Mixture of Long-Term and Transiently Reconstituting Multipotent Progenitors
(A) Five GFP+CD45.2+ donor cells were transplanted into irradiated CD45.1+ recipient mice along with 200,000 CD45.1+ recipient bone marrow cells. Each line
represents the frequency of donor-derived blood cells in a single recipient mouse.
(B) Summary of the primary transplantation results from (A).
(C) Twenty-five GFP+CD45.2+ donor cells were competitively transplanted into irradiated CD45.1+ recipient mice.
(D) Summary of the results in (C).
(E) The frequencies of donor-derived hematopoietic stem and progenitor cells in the bone marrow of mice reconstituted by 25 MPP-1 cells at 17 weeks after
transplantation.
(F) Summary of secondary transplantation experiments. Five million bone marrow cells from primary recipients of 25 MPP-1 cells were transplanted into four
secondary recipient mice per primary recipient mouse.
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In Vivo
We analyzed donor chimerism in the myeloid (Mac-1+), erythroid
(CD71+), megakaryocyte (CD41+CD61+), or B (B220+) cell110 Cell Stem Cell 13, 102–116, July 3, 2013 ª2013 Elsevier Inc.lineages in the bone marrow of recipient mice 10 days after
transplantation. Each recipient mouse was transplanted with
30 donor HSC-1, HSC-2, MPP-1, MPP-2, MPP-3, HPC-1, or
HPC-2 cells without any competitor cells. We detected virtually
Cell Stem Cell
SLAM Markers Distinguish HSC/MPP Heterogeneityno donor-derived progeny from HSC-1 cells, consistent with
other data indicating that this is a very primitive and quiescent
population (Figure S5B). HSC-2 cells gave rise to low levels of
donor myeloid, erythroid, megakaryocyte, and B cells, indicating
that these cells are more readily activated after transplantation
than HSC-1 cells (Figure S5B). MPP-1, MPP-2, and MPP-3 cells
all tended togive higher levels of reconstitution in all lineages than
HSC-2 cells, indicating that these populations are more mature
than HSCs while remaining multipotent and able to form both
erythrocytes and megakaryocytes (Figure S5B). HPC-1 cells
formed primarily B cells and some myeloid cells, but few, if any,
erythroid or megakaryocyte lineage cells. HPC-2 cells formed
very low levels of cells in multiple lineages, including myeloid
cells, B cells, and megakaryocyte lineage cells (Figure S5B).
Colony Forming Potential
To investigate the clonogenic potential of individual cells in each
stem and progenitor cell population without regard to whether
they have sufficient reconstituting activity to be detected in vivo,
we assessed colony formation in culture. As expected, 91% ±
1.2% and 96% ± 1.2% of HSC-1 and HSC-2 cells formed
colonies, usually large mixed myeloid, myeloerythroid, and/or
megakaryocyte colonies (Figure 7A). Among MPPs, 64%–72%
of cells in each population formed colonies, mainly myeloid
or mixed myeloerythroid and/or megakaryocyte colonies (Fig-
ure 7A). Thus, most MPP-1, MPP-2, and MPP-3 cells had the
potential to formmyeloid cells and at least 10%–20% of the cells
in each population were able to form erythrocytes and/or
megakaryocytes.
Only 24% ± 2.4% of HPC-1 cells and 37% ± 12% of HPC-2
cells formed colonies in culture (Figure 7A). None of the colonies
contained erythrocytes ormegakaryocytes.When these data are
combined with the lymphoid-restricted reconstitution patterns
observed from HPC-1 cells in vivo (Figures 6D and 6F), the
data suggest that HPC-1 cells include a mixture of myeloid-
restricted progenitors and lymphoid-restricted progenitors that
have largely lost the potential to make erythrocytes or megakar-
yocytes. Alternatively, a minority of HPC-1 cells may be multipo-
tent progenitors whose ability to reconstitute themyeloid lineage
is very limited and cannot be detected from small numbers
of HPC-1 cells in vivo. HPC-2 cells formed mainly small mega-
karyocyte colonies (5–20 cells), as well as smaller numbers of
mixed myeloerythroid and/or megakaryocyte colonies (Fig-
ure 7A), consistent with the reconstitution data observed in vivo
(Figures 6E and 6F).
Quiescent HSCs AreMaintained by a Perivascular Niche
To test whether quiescent HSCs depend upon a perivascular
niche, we assessed the depletion of HSC-1 and HSC-2 cells
from Tie2-Cre; Lepr-Cre; Scffl/mice. Relative to wild-type con-
trols, both HSC-1 and HSC-2 cells were significantly depleted in
Tie2-Cre; Scffl/mice, in Lepr-Cre; Scffl/mice, and in Tie2-Cre;
Lepr-Cre; Scffl/ mice (Figure 7C). Almost no HSC-1 cells could
be found in the bone marrow of Tie2-Cre; Lepr-Cre; Scffl/mice
and the ratio of HSC-1/HSC-2 cells was significantly lower in
Tie2-Cre; Lepr-Cre; Scffl/mice as compared to mice with other
genotypes (Figure 7C). MPP-1, MPP-2, and MPP-3 cells, but not
HPC-1 cells, were also depleted from the bone marrow of Tie2-
Cre; Lepr-Cre; Scffl/ mice (Figure S7A). Most HSCs, includingquiescent HSC-1 cells, are therefore maintained by a perivascu-
lar niche.
The number of HSC-1 and HSC-2 cells in the spleen of Tie2-
Cre; Lepr-Cre; Scffl/ mice was significantly higher than in litter-
mate controls, but most of this increase came from HSC-2 cells
(Figure S7B). We did not detect a significant change in the fre-
quency of HSC-1 or HSC-2 cells in the blood of Tie2-Cre;
Lepr-Cre; Scffl/ mice (data not shown). Despite the increase in
the spleen, the total number of HSC-1 and HSC-2 cells in Tie2-
Cre; Lepr-Cre; Scffl/ mice significantly declined relative to
controls (Figure S7B). Consistent with this, Tie2-Cre; Lepr-Cre;
Scffl/ mice became anemic and white blood cell counts
declined upon aging (Figure S7E).
We transplanted 300,000 bone marrow cells from each of
these genetic backgrounds along with 300,000 recipient bone
marrow cells into irradiated recipient mice. Relative to mice
transplanted with wild-type control bone marrow, the levels of
donor cell reconstitution were significantly reduced in mice
transplanted with bone marrow from Tie2-Cre; Scffl/ mice,
Lepr-Cre; Scffl/ mice, or Tie2-Cre; Lepr-Cre; Scffl/ mice (Fig-
ure 7D). Fourteen of 15 recipients of wild-type cells and 18 of
20 recipients of Scffl/ control cells were long-term multilineage
reconstituted by donor cells. In contrast, only 14 of 19, 10 of 19,
and 6 of 19 mice were long-term multilineage reconstituted by
donor cells from Tie2-Cre; Scffl/ mice, Lepr-Cre; Scffl/ mice,
and Tie2-Cre; Lepr-Cre; Scffl/ mice, respectively (Figure 7E).
Using these data, we calculated HSC frequencies based on
Poisson statistics (Smith et al., 1991). Relative to wild-type litter-
mates, this indicated an approximately 50% decline in HSC
frequency in Tie2-Cre; Scffl/ bone marrow, 70% in Lepr-Cre;
Scffl/ bone marrow, and 85% in Tie2-Cre; Lepr-Cre; Scffl/
bone marrow (Figure 7E).
Five million bone marrow cells from three primary recipients in
each treatment were transplanted into three to four secondary
recipients each. All secondary recipients of Scffl/ bone marrow
cells were long-term multilineage reconstituted by donor cell,
whereas 9 of 10, 5 of 12, and none of 12 recipients were long-
term multilineage reconstituted by Tie2-Cre; Scffl/ bone
marrow, Lepr-Cre; Scffl/ bone marrow, or Tie2-Cre; Lepr-Cre;
Scffl/ bone marrow, respectively (Figure S7D). The failure of
Tie2-Cre; Lepr-Cre; Scffl/ bone marrow cells to give long-term
multilineage reconstitution of any secondary recipients is consis-
tent with the analysis of HSC-1 and HSC-2 frequencies and con-
firms that the vast majority of HSCs in the bone marrow,
including most quiescent HSCs, depend upon a perivascular
niche for their maintenance.
DISCUSSION
The CD150, CD48, CD229, and CD244 SLAM family markers are
differentially expressed among LSK cells in a manner that distin-
guishes functionally distinct subpopulations of HSCs and MPPs
(Figures7BandS7F). Prior useofmarkers suchasCD150expres-
sion level (Morita et al., 2010), CD34 expression (Osawa et al.,
1996), Flk2 expression (Christensen and Weissman, 2001; Yang
et al., 2005), and a2 integrin expression (Benveniste et al., 2010)
distinguished functionally distinct subpopulations of HSCs and
MPPs. However, many subsets of HSCs and MPPs remained
heterogeneous, such that certain subpopulations were largelyCell Stem Cell 13, 102–116, July 3, 2013 ª2013 Elsevier Inc. 111
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Figure 6. MPP-2 and MPP-3 Cells Are Transiently Reconstituting Multipotent Progenitors while HPC-1 and HPC-2 Cells Contain a
Heterogeneous Mix of Restricted Progenitors
(A and B) Twenty-five GFP+CD45.2+ MPP-2 (A) or MPP-3 (B) donor cells were transplanted into irradiated CD45.1+ recipient mice along with 200,000 CD45.1+
recipient bone marrow cells. Each line represents the frequency of donor-derived blood cells in a single recipient.
(legend continued on next page)
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Figure 7. Quiescent HSC-1 Cells Are Maintained by a Perivascular Niche in which Scf Is Expressed by Endothelial and Perivascular Stromal
Cells
(A) Colony formation assay. Forty-eight cells from each HSC, MPP, and HPC fraction were sorted, one cell per well. Large (>2mm in diameter), medium (>1mm in
diameter), and small (<1 mm in diameter) colonies were counted (left, mean ± SD) and their composition assessed by Giemsa staining after 14 days of culture
(right, mean ± SD). g, granulocyte; m, macrophage; E, erythroblasts; M, megakaryocyte. Data represent six independent experiments.
(B) Schematic summarizing the self-renewal potentials of each fraction of hematopoietic stem and progenitor cells distinguished using SLAM family markers.
(C) The number of HSC-1 and HSC-2 cells in femurs and tibias from 5- to 10-month-old adult wild-type (WT), Scf fl/ (Het), Tie2-cre; Scffl/ (Tie2), Lepr-cre; Scffl/
(Lepr), and Tie2-cre; Lepr-cre;Scffl/ (Double) mice (left). Statistical significance was separately analyzed for HSC-1 cells (black bars) and HSC-2 cells (gray bars).
The ratio of HSC-1 to HSC-2 cells (right) is shown. Data represent mean ± SD from three independent experiments.
(D) We transplanted 300,000 donor bone marrow cells from each genetic background into irradiated recipient mice along with 300,000 recipient bone marrow
cells. Data represent mean ± SD from four independent experiments with a total of 15–20 recipient mice per genotype.
(E) Summary of reconstitution results from (D). Recipient mice were considered long-term multilineage reconstituted if donor myeloid, B, and T cells represented
more than 1% of blood cells in each lineage 16 weeks after transplantation. *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t test. See also Figure S7.
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SLAM Markers Distinguish HSC/MPP Heterogeneitycharacterized through retrospective analysis of reconstitution
patterns in irradiated mice (Copley et al., 2012). The multiplexing
of SLAM family markers distinguishes multiple subsets of HSCs(C) Summary of the reconstitution results from (A) and (B).
(D and E) Twenty-five GFP+CD45.2+ HPC-1 (D) or HPC-2 (E) donor cells were tra
recipient bone marrow cells. Each line represents the frequency of donor-derive
(F) Summary of the reconstitution results from (D) and (E). See also Figures S5 aandMPPs that differ in terms of reconstituting potential and other
functional properties, allowing each subpopulation to be pro-
spectively isolated to a high degree of purity.nsplanted into irradiated CD45.1+ recipient mice along with 200,000 CD45.1+
d blood cells in a single recipient.
nd S6.
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Cell Stem Cell
SLAM Markers Distinguish HSC/MPP HeterogeneityHSC-1 cells were the most quiescent (Figure 2) and gave
mainly myeloid-biased reconstitution (Figures 3F, S4E, and
S4F). HSC-2 cells divided more frequently and gave mainly
lymphoid-biased reconstitution (Figures 2, 3G, S4E and S4F).
MPP-1 cells gave transient multilineage reconstitution, including
myeloid reconstitution for up to 8 weeks after transplantation
(Figures 5A–5D). MPP-1 cells self-renewed and formed all
MPP and HPC populations but never formed HSC-1 cells and
almost never formed HSC-2 cells (Figure 5E). MPP-2 cells con-
tained transiently reconstituting multipotent progenitors that
reconstituted the myeloid lineage for up to 6 weeks after trans-
plantation (Figures 6A and 6C). MPP-3 cells gave transient multi-
lineage reconstitution, including myeloid reconstitution for up
to 4 weeks after transplantation (Figures 6B and 6C). MPP-1,
MPP-2, and MPP-3 cells all gave rise to both megakaryocytes,
platelets, and erythrocytes, in vitro and in vivo, even when only
five cells from these populations were transplanted into irradi-
ated mice (Figures 5A–5C, 6A–6C, 7A, and S5B).
The ability of Flt3+LSK MPPs to make megakaryocytes and
erythrocytes has been debated (Adolfsson et al., 2005; Forsberg
et al., 2006; Boyer et al., 2011). One complication is that Flt3+LSK
cells are heterogeneous and prior in vivo studies injected
50–10,000 cells into irradiated mice to test developmental
potential (Adolfsson et al., 2005; Yang et al., 2005; Forsberg
et al., 2006; Luc et al., 2008). The inability to perform a clonal,
or near clonal, analysis of developmental potential in vivo
made it difficult to take into account the heterogeneity within
the population. Our data indicate that SLAM family markers
can resolve Flt3+CD34+LSK cells into a hierarchy of at least
four functionally distinct subpopulations contained within the
MPP-2, MPP-3, HPC-1, and HPC-2 populations (Figure S5A).
Consistent with prior studies (Adolfsson et al., 2005), most
Flt3+LSK cells were contained within the HPC-1 population (Fig-
ures S2A and S5A) and the Flt3+ subset of HPC-1 cells formed
myeloid and/or B cells but not platelets or erythrocytes (Figures
S6D and S6F). What remains uncertain from our data is whether
these Flt3+ HPC-1 cells include multipotent cells with both
myeloid and lymphoid potential or a mixture of lymphoid-
restricted and myeloid-restricted progenitors.
Consistent with other published studies (Forsberg et al., 2006;
Boyer et al., 2011), both MPP-2 and MPP-3 cells included
Flt3+CD34+LSK cells (Figures S2A and S5A) and the Flt3+
MPP-2 and MPP-3 cells gave transient multilineage reconsti-
tution that included platelets and erythrocytes (Figures S6A–
S6C). Our data therefore suggest that there are multiple popula-
tions of Flt3+ MPPs that retain erythroid, megakaryocytic,
myeloid, and lymphoid potential, though this does not rule out
the possibility of an even more mature MPP within the HPC-1
fraction whosemyeloid reconstituting activity is difficult to detect
in vivo but that nonetheless forms myeloid and lymphoid cells
while lacking erythroid and megakaryocytic potential.
Using the new SLAM family markers, we found that quiescent
HSC-1 cells are even more dependent upon SCF expression by
endothelial cells and perivascular stromal cells than HSC-2 cells
(Figures 7C–7E and S7D). Elimination of vascular and perivascu-
lar SCF expression in Tie2-Cre; Lepr-Cre; Scffl/mice eliminated
nearly all HSC-1 cells and most HSC-2 cells. Consistent with
this, cells that gave long-term multilineage reconstitution in pri-
mary and secondary recipient mice were profoundly depleted114 Cell Stem Cell 13, 102–116, July 3, 2013 ª2013 Elsevier Inc.in the bone marrow of Tie2-Cre; Lepr-Cre; Scffl/ (Figures 7D
and 7E) and these mice developed anemia upon aging (Fig-
ure S7E). Most or all quiescent HSCs aremaintained in a perivas-
cular niche by factors secreted by endothelial and perivascular
stromal cells.
EXPERIMENTAL PROCEDURES
Mice
For reconstitution assays, donor cells were isolated from 8- to 12-week-old
UBC-GFPmice (Schaefer et al., 2001) that were backcrossed at least six times
onto a C57BL/Ka-CD45.2:Thy1.1 background. Recipient mice were C57BL/
Ka-CD45.1:Thy1.2, greater than 8 weeks old, unless otherwise mentioned.
For cell surface marker analysis, Ki-67 and PI staining, BrdU incorporation
assays, and in vitro colony formation assays, cells were obtained from
C57BL/Ka-CD45.2:Thy1.1 mice. Col1A1-H2B-GFP (Foudi et al., 2009) and
Rosa26-M2-rtTA (Hochedlinger et al., 2005) transgenic mice were used for
H2B-GFP label retention assays. For conditional Scf deletion analysis, we
crossed Scffl mice (Ding et al., 2012) with Tie2-Cre (Koni et al., 2001) and
Lepr-Cre (DeFalco et al., 2001) mice. All mice used in this study were housed
in the Unit for Laboratory Animal Medicine at the University ofMichigan (UM) or
in the Animal Resource Center at the University of Texas Southwestern
Medical Center (UTSW). All procedures were approved by the UM Committee
on the Use andCare of Animals and by the UTSW Institutional Animal Care and
Use Committee.
Flow Cytometry
Bone marrow cells were flushed from tibias and femurs using Hank’s
balanced salt solution (HBSS, Invitrogen) without calcium or magnesium,
supplemented with 1% head-inactivated calf serum (GIBCO). When we
flushed bones, we drilled a hole in the intact bone using a needle and did
not clip off the epiphyses. Bone marrow cells were sometimes obtained by
crushing tibias, femurs, pelvic bones, and vertebrae with a mortar and
pestle. Both methods gave indistinguishable results. Cells were gently
triturated and filtered through a nylon screen (45 mm, Sefar America) to obtain
a single-cell suspension. Lineage markers were anti-CD2, anti-CD3ε,
anti-CD5, anti-CD8a, anti-B220, anti-Gr-1, and anti-Ter119. Anti-CD41 was
included in the lineage cocktail when staining HSCs from young adult
mice, but not from older mice (such as in the niche experiments) due to
the increase in CD41 expression by HSCs with age. In older mice, CD41
was stained separately to exclude CD41high megakaryocyte lineage cells.
Bone marrow cells were incubated with biotinylated antibodies against
lineage markers, followed by anti-biotin microbeads, and Lineage+ cells
were depleted by autoMACS (Miltenyi Biotec). The fraction enriched for
Lineage/low cells was further incubated with phycoetythrin (PE)-Cy7-conju-
gated anti-CD150 antibody, fluorescein isothiocyanate (FITC)-conjugated
anti-CD48, allophycocyanin (APC)-conjugated anti-CD229, PE-conjugated
anti-CD244, Alexa Fluor 700-conjugated anti-Sca-1, APC-eFluor 780-conju-
gated anti-c-Kit, and streptavidin PE-Texas Red. Dead cells were excluded
by staining with 4’, 6-diamidino-2-phenylindole (DAPI, Sigma). All antibodies
are listed in Table S1.
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